Rekombinanter ITGA4 (Natalizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter ITGA4 (Natalizumab Biosimilar) Antikörper (ABIN7795116)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Natalizumab Biosimilar, Integrin alpha 4 Monoclonal Antibody
-
Produktmerkmale
- Natalizumab Biosimilar uses the same protein sequences as the therapeutic antibody natalizumab. Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human Integrin alpha 4
-
-
anti-ITGA4 (Natalizumab Biosimilar) antibody
Research Grade Reaktivität: Human FACS Wirt: Humanized Monoclonal unconjugated Recombinant Antibody
anti-ITGA4 (Natalizumab Biosimilar) antibodyReaktivität: Human FACS, BR Wirt: Kaninchen Chimeric unconjugated Recombinant Antibody
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- ITGA4 (Natalizumab Biosimilar)
-
Andere Bezeichnung
- Natalizumab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-
